While GLP-1s such as tirzepatide, semaglutide, and dulaglutide are known to reduce cardiovascular and all-cause mortality in patients with type 2 diabetes, their effects in patients who also have OSA remain unclear
Going forward, Dr Reddy's plans to launch generic version of semaglutide in more than 70 countries over the next two years
Lillys triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Peer review Peer review information Nature Reviews Endocrinology thanks Roger Adan, Ya-Xiong Tao and the other, anonymous, reviewer(s) for their contribution to the peer review of this work
This section investigates the particular benefits noted in clinical trials, emphasizing glycemic control and enhancements in lipid profiles
L-Carnitin-Sirup gibt es hier